

PERSONAL INFORMATION

Simona Osella Abate



📍 Pathology Unit, Dept. Medical Sciences
University of Turin
Via Santena 7
10126 Torino
Italy

☎ 011 6336860 (Lab) 📠 3475492599

✉ simona.osellaabate@unito.it

Sex Female | Date of birth 05/05/1973 | Nationality Italian

WORK EXPERIENCE

14/07/2006-to date

Research Technician

University of Turin, Dermatology Section, Turin

- Mutational analyses on solid tumors, Survival statistical analyses

28/12/1998-13/07/2006

Post-graduate Research Fellow

University of Turin, Dermatology Section, Turin

- Project Title: MIUR A07.020 “Valutazione del m-RNA della tirosinasi in pazienti affetti da melanoma. Studio su sangue periferico e su linee cellulari. Correlazione con decorso clinico e con le modificazioni indotte da terapia”

EDUCATION AND TRAINING

06/11/2002

Specialization in Clinical Biochemistry
(70/70 with highest honours) University of Turin

10/07/1997

Master Degree in Biological Sciences (106/110)
University of Torino, Torino (Italy)

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B1	B1	B1	B1	B1
French	A2	A2	A2	A2	A2

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
[Common European Framework of Reference for Languages](#)

Communication skills Good capability of social interaction with collaborators

Organisational / managerial skills	Good experience in project or team management; undergraduate students training and thesis development
Job-related skills	PCR technology assays development; DNA and RNA extraction from cell lines, FFPE tissues, blood. Sanger sequencing. Sequenom MassARRAY system technology. Liquid biopsy; circulating free DNA analysis from blood, Real-time PCR. Survival statistical analyses.
Digital skills	▪ Microsoft OS and Office, STATA 15 Statistical Software
Driving licence	B

ADDITIONAL INFORMATION

Publications	<ol style="list-style-type: none"> 1. Macrophage-mediated immunostimulation modulates therapeutic efficacy of IL-2 based chemoimmunotherapy in advanced metastatic melanoma (MM) patients. Bernengo MG, Quaglino P, Cappello N, Lisa F, Osella-Abate S, Fierro MT. <i>Melanoma Res</i> 2000; 10(1):55-65. 2. Immature myeloid precursors in chronic neutrophilic dermatosis associated with myelodysplastic syndrome. Tomasini C, Aloï F, Osella-Abate S, Dapavo P, Pippione M. <i>Am J Dermatopathol</i> 2000; 22(5):429-33. 3. What Is Your Diagnosis? (Myelodysplastic Syndrome, preleukemic myelogenous leukaemia). Tomasini C, Osella-Abate S, Novelli M. <i>Dermatopathology: Practical & Conceptual</i> 2000; 6(4): 369-371. 4. Role of RT-PCR tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. Osella-Abate S, Savoia P, Cambieri I, Salomone B, Quaglino P, Bernengo MG. <i>Melanoma Res</i> 2000; 10(6):545-555. 5. Expression of apoptosis markers on peripheral blood lymphocytes from CTCL patients during extracorporeal photochemotherapy. Osella-Abate S, Zaccagna A, Savoia P, Quaglino P, Salomone B, Bernengo MG. <i>J Am Acad Dermatol</i> 2001; 44: 40-47. 6. CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients. Fierro MT, Novelli M, Savoia P, Cambieri I, Quaglino P, Osella-Abate S, Bernengo MG. <i>J Cutan Pathol</i> 2001; 28: 356-362. 7. Peripheral blood involvement in a mycosis fungoides patient with limited skin lesions: phenotypical features and homing molecule pattern. Quaglino P, Osella-Abate S, Novelli M, Lisa F, Comessatti A, Bernengo MG. <i>Eur J Dermatol</i> 2001; 11(6): 560-563. 8. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid prodrug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Salomone B, Ponti R, Gasco MR, Ugazio E, Quaglino P, Osella-Abate S, Bernengo MG. <i>Clin Exp Metastasis</i> 2000; 18 (8): 663-673. (Published 2001) 9. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. <i>Melanoma Res</i> 2002; 12 (4): 325-334. 10. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated to a poor prognosis: a clinical follow-up study of 110 patients. Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Leporati C, Ortoncelli M, Bernengo MG. <i>Br J Cancer</i> 2003; 89 (8): 1457-62. 11. Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG. <i>Melanoma Res</i> 2004; 14(2): s17-s19. 12. RT-PCR tyrosinase expression in the peripheral blood of melanoma patients. Quaglino P, Savoia P, Osella-Abate S, Bernengo MG. <i>Expert Rev Mol Diagn.</i> 2004; 4(5): 727-41. 13. Tyrosinase mRNA RT-PCR analysis as an additional diagnostic tool for the identification of
--------------	---

- melanoma cells in biological fluid samples other than blood: a preliminary report. Savoia P, Quaglino P, **Osella-Abate S**, Comessatti A, Nardò T, Bernengo MG. *Int j Biol Markers* 2005; 20 (1): 11-17.
14. Time course and pattern of first relapse in stage I-II primary cutaneous melanoma: a multivariate analysis of disease-free survival in 3,174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004. Bernengo MG, Quaglino P, Cappello N, Fierro MT, Doveil GC, Macripò G, **Osella-Abate S**, Peroni A, Lisa F, Savoia P. *G Ital Dermatol Venereol* 2005; 140: 191-200.
15. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary Syndrome. Fierro MT, Comessatti A, Quaglino P, Ortoncelli M, **Osella-Abate S**, Ponti R, Novelli M, Bernengo MG. *Dermatology* 2006; 213 (4): 284-292.
16. Melanoma and pregnancy: a 30-year experience at the Turin melanoma centre and a review of the literature data. Savoia P, Ortoncelli M, **Osella-Abate S**, Quaglino P, Mola F, Fierro MT, Bernengo MG. *G Ital Dermatol Venereol* 2007; 142:1-7.
17. Serum levels of the Th1 promoter IL-12 and Th2 Chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/Toxic epidermal necrolysis and correlate with soluble Fas Ligand expression: an immunoenzymatic study from the Italian Group of Immunopathology. Quaglino P, Caproni M, Antiga E, Del Bianco E, **Osella-Abate S**, Savoia P, Frezzolini A, Schena D, Marzano A, Volpi W, De Simone C, Parodi A, Fabbri P, Bernengo MG. *Dermatology* 2007; 214 (4):296-304.
18. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Quaglino P, **Osella-Abate S**, Cappello N, Ortoncelli M, Nardò T, Fierro MT, Cavallo F, Savoia P, Bernengo MG. *Melanoma Research* 2007; 17(2): 75-82.
19. Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status. Savoia P, **Osella-Abate S**, Comessatti A, Nardò T, Marchiò C, Pacchioni D, Quaglino P, Bernengo MG. *J Clin Pathol* 2008;61(2):179-83 (Published Online First: 3 August 2007. doi:10.1136/jcp.2007.049577)
20. Electrochemotherapy with Intravenous Bleomycin in the Local Treatment of Skin Melanoma Metastases. Quaglino P, Mortera C, **Osella-Abate S**, Barberis M, Illengo M, Rissone M, Savoia P, Bernengo MG. *Ann Surg Oncol* 2008; 15(8):2215-22
21. CDKN2a mutations and MC1R variants in italian patients with single or multiple primary melanoma. Pastorino L, Bonelli L, Ghorzo P, Queirolo P, Battistuzzi L, Nasti S, Gargiulo S, Gliori S, Savoia P, **Osella-Abate S**, Bernengo MG, Bianchi Scarrà G. *Pigment Cell and Melanoma Research* 2008; 21(6):700-9
22. Skin metastases of malignant melanoma: a clinical and prognostic survey. Savoia P, Fava P, Nardò T, **Osella-Abate S**, Quaglino P, Bernengo MG. *Melanoma Research* 2009; 19(5):321-6.
23. Vitiligo is an independent favourable prognostic factor in stage iii and iv metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Quaglino P, Marengo F, **Osella-Abate S**, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG. *Ann Oncol*. 2010 Feb;21(2):409-14.
24. Melanoma of unknown primary site: a 33-year experience at the Turin melanoma centre. Savoia P, Fava P, **Osella-Abate S**, Nardò T, Comessatti A, Quaglino P, Bernengo MG. *Melanoma Research* 2010; 20(3):227-32.
25. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphea. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, **Osella-Abate S**, De Simone C, Marzano A, Bernengo Mg, Fabbri P, Caproni M. *Br J Dermatol* 2010;162(5):1056-63.
26. Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: a single centre observational cohort study. Quaglino P, Ribero S, **Osella-Abate S**, Macrì L, Grassi M, Caliendo V, Ascoli S, Sapino A, Macripò G, Savoia P, Bernengo MG. *J Surg Oncol* 2011; 20(4):259-64
27. Skin cancers and other cutaneous diseases in renal transplant recipients: a single italian center observational study. Savoia P, Stroppiana E, Cavaliere G, **Osella-Abate S**, Mezza E, Segoloni GP,

- Bernengo MG. *EJD* 2011; 21(2):242-7.
28. microRNA-214 contributes to melanoma tumor progression through suppression of TFAP2C. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Polisenso L, **Osella-Abate S**, De Pittà C, Pinatel E, Provero P, Bernengo MG, Osman I, Taverna D. *EMBO* 2011; 30(10):1990-2007.
29. Disease progression in melanoma patients with negative sentinel lymph node: does false-negative specimens entirely account for this phenomenon? Savoia P, Fava P, Caliendo V, **Osella-Abate S**, Ribero S, Quaglino P, Macripò G, Bernengo MG. *J EADV* 2012;26(2):242-8
30. Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study. Savoia P, **Osella-Abate S**, Deboli T, Marengo F, Stroppiana E, Novelli M, Fierro MT, Bernengo MG. *J EADV* 2012; 26(7):882-8
31. Circulating CD4+CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients. Quaglino P, Antiga E, Comessatti A, Caproni M, Nardò T, Ponti R, Novelli M, **Osella-Abate S**, Fabbri P, Bernengo MG. *Arch Dermatol Res* 2012; 304(8):639-45
32. Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes. Ribero S, Quaglino P, **Osella-Abate S**, Sanlorenzo M, Senetta R, Macri L, Savoia P, Macripò G, Sapino A, Bernengo MG. *J EADV* 2013;27(9):1132-7
33. Inclusion complex of 4-hydroxyonanal with a polymeric derivative of beta-cyclodextrin enhances the anti-tumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model. Pizzimenti S, Ciamporcero E, Pettazoni P, **Osella-Abate S**, Novelli M, Toaldo C, Husse M, Daga M, Minelli R, Bisazza A, Ferruti P, Ranucci E, Bernengo MG, Dianzani C, Biasi F, Cavalli R, Barrera G. *Free Radical Biology and Medicine* 2013 Dec;65:765-77.
34. Melanoma in patients younger than 20 years. *G Ital Dermatol Venereol*. Sanlorenzo M, Ribero S, **Osella-Abate S**, Balagna EM, Caliendo V, Macripò G, Bernengo MG, Quaglino P. *GIDV* 2013 Dec;148(6):667-72.
35. Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. *Br J Dermatol*. 2013 Dec;169(6):1240-5. Ribero S, **Osella-Abate S**, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G, Tomasini C, Senetta R, Macripò G, Bernengo MG, Quaglino P.
36. Eruptive dermal clear cell desmo-plastic mesenchymal tumors with perivascular myoid differentiation in a young boy. A clinical, histopathologic, immunohistochemical and electron microscopy study of 17 lesions. Tomasini C, Metze D, **Osella-Abate S**, Novelli M, Kutzner H. *J Cutan Pathol*. 2014 Feb;41(2):123-33.
37. Melanoma immunotherapy. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. *Cancer Biol Ther*. 2014 Jun 1;15(6):665-74.
38. Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. Sanlorenzo M, **Osella-Abate S**, Ribero S, Marengo F, Nardò T, Fierro MT, Novelli M, Cervetti O, Bernengo MG, Quaglino P. *Int J Dermatol*. 2015 Sep;54(9):1023-9. doi: 10.1111/ijd.12730.
39. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, **Osella-Abate S**, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. *J Am Acad Dermatol*. 2014 Dec;71(6):1102-1109.
40. Prognostic differences across sexes in melanoma patients: what has changed from the past? Sanlorenzo M, Ribero S, **Osella-Abate S**, Zugna D, Marengo F, Macripò G, Fierro MT, Bernengo MG, Quaglino P. *Melanoma Res*. 2014 Dec;24(6):568-76.
41. Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up. Novelli M, Fava P, Sarda C, Ponti R, **Osella-Abate S**, Savoia P, Bergallo M, Lisa F, Fierro MT, Quaglino P. *Am J Clin Pathol*. 2015 Jan;143(1):57-69.
42. Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role? Ribero S, **Osella-Abate S**, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, Macripò G, Macri L, Sapino A, Quaglino P. *Ann Surg Oncol*. 2015;22(6):1967-73.

43. Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. **Osella-Abate S**, Ribero S, Sanlorenzo M, Maule MM, Richiardi L, Merletti F, Tomasini C, Marra E, Macripò G, Fierro MT, Quaglino P. *Int J Cancer*. 2015 May 15;136(10):2453-7.
44. The risk of melanoma in airline pilots and cabin crew: a meta-analysis. Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, **Osella-Abate S**, Quaglino P, Cleaver JE, Ortiz-Urda S. *JAMA Dermatol*. 2015 Jan;151(1):51-8
45. Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D Models. Pizzimenti S, Daga M, Ciamporcerio E, Toaldo C, Pettazzoni P, **Osella-Abate S**, Novelli M, Minelli R, Bisazza A, Gamba P, Testa G, Ullio C, Ferruti P, Ranucci E, Bernengo MG, Ferretti C, Dianzani C, Biasi F, Barrera G, Cavalli R. *J Biomed Nanotechnol*. 2015 Dec;11(12):2169-85.
46. Genetic mutations in primary malignant melanoma of the esophagus: case report and literature review. Sanlorenzo M, Ribero S, **Osella Abate S**, Mariani S, Strignano P, Salizzoni M, Savoia P, Fierro MT, Quaglino P. *G Ital Dermatol Venereol*. 2015 Oct 20 [Epub ahead of print]
47. Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status: A Systematic Review and Meta-analysis. Ribero S, Gualano MR, **Osella-Abate S**, Scaioli G, Bert F, Sanlorenzo M, Balagna E, Fierro MT, Macripò G, Sapino A, Siliquini R, Quaglino P. *JAMA Dermatol*. 2015 Dec 1;151(12):1301-1307. doi: 10.1001/jamadermatol.2015.2235.
48. Prediction of high naevus count in a healthy U.K. population to estimate melanoma risk. Ribero S, Zugna D, **Osella-Abate S**, Glass D, Nathan P, Spector T, Bataille V. *Br J Dermatol*. 2016 Feb;174(2):312-8.
49. Novel CALR somatic mutations in essential thrombocythaemia. Riera L, **Osella-Abate S**, Benevolo G, Beggiano E, Ferrero S, Pich A, Francia di Celle P. *Br J Haematol*. 2016 Jun;173(5):797-801.
50. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. Quaglino P, Fava P, Caproni M, Antiga E, De Simone C, Papini M, Parodi A, Novelli M, **Osella-Abate S**, Ribero S, Sanlorenzo M, Ponti R, Fierro MT, Marzano AV, Savoia P. *J Eur Acad Dermatol Venereol*. 2016 Apr;30(4):655-8
51. Prognostic Role of Multiple Lymphatic Basin Drainage in Sentinel Lymph Node-Negative Trunk Melanoma Patients: A Multicenter Study from the Italian Melanoma Intergroup. Ribero S, **Osella-Abate S**, Pasquali S, Rossi CR, Borgognoni L, Piazzalunga D, Solari N, Schiavon M, Brandani P, Ansaloni L, Ponte E, Silan F, Sommariva A, Bellucci F, Macripò G, Quaglino P. *Ann Surg Oncol*. 2016 May;23(5):1708-15.
52. Squamocellular Carcinoma of the Skin: Clinicopathological Features Predicting the Involvement of the Surgical Margins and Review of the Literature. Ribero S, **Osella Abate S**, Di Capua C, Dika E, Balagna E, Senetta R, Picciotto F, Tomasini C, Macripò G, Quaglino P. *Dermatology*. 2016;232(3):279-84.
53. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Bustreo S, **Osella-Abate S**, Cassoni P, Donadio M, Airoidi M, Pedani F, Papotti M, Sapino A, Castellano I. *Breast Cancer Res Treat*. 2016 Jun;157(2):363-371. doi: 10.1007/s10549-016-3817-9
54. Prognostic role of histological regression in cutaneous melanoma. Ribero S, **Osella-Abate S**, Dika E, Sportoletti Baduel E, Marra E, Picciotto F, Caliendo V, Fierro MT, Quaglino P. *G Ital Dermatol Venereol*. 2016 Nov 15. [Epub ahead of print]
55. Effects of sex on naevus body distribution and melanoma risk in two melanoma case-control studies at different latitudes. Ribero S, **Osella-Abate S**, Reyes-Garcia D, Glass D, Bataille V. *Br J Dermatol*. 2017 Apr;176(4):1093-1094. Epub 2017 Feb 7.
56. Sentinel lymph node biopsy in cutaneous melanoma. Ribero S, Sportoletti Baduel E, **Osella-Abate S**, Dika E, Quaglino P, Picciotto F, Macripò G, Bataille V. *G Ital Dermatol Venereol*. 2017 Aug;152(4):355-359.
57. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Quaglino P,

- Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, **Osella-Abate S**, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y. *Ann Oncol.* 2017 Oct 1;28(10):2517-2525. doi: 10.1093/annonc/mdx352.
58. Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study. Ribero S, Podlipnik S, **Osella-Abate S**, Sportoletti-Baduel E, Manubens E, Barreiro A, Caliendo V, Chavez-Bourgeois M, Carrera C, Cassoni P, Malveyh J, Fierro MT, Puig S. *Eur J Cancer.* 2017 Nov;85:59-66.
59. Multiple Lymph Node Basin Drainage in Trunk Melanoma Is Not Associated with Survival of Sentinel Lymph Node-Positive Patients. Ribero S, **Osella Abate S**, Pasquali S, Rossi CR, Borgognoni L, Piazzalunga D, Solari N, Schiavon M, Brandani P, Ansaloni L, Ponte E, Silan F, Sommariva A, Bellucci F, Macripò G, Quaglino P; Italian Melanoma Intergroup (IMI). *Dermatology.* 2017;233(2-3):205-211.
60. The large spectrum of spitzoid tumours: a retrospective survival study. Broganelli P, Ribero S, Castagno I, Ricceri F, Deboli T, Marra E, Tomasini C, Sacerdote C, **Osella-Abate S**, Sanlorenzo M, Quaglino P, Fierro MT. *G Ital Dermatol Venereol.* 2017 Jul 11. doi: 10.23736/S0392-0488.17.05575-4. [Epub ahead of print]
61. Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. Mariani S, Bertero L, **Osella-Abate S**, Di Bello C, Francia di Celle P, Coppola V, Sapino A, Cassoni P, Marchiò C. *Br J Cancer.* 2017 Jul 25;117(3):358-366.
62. Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis. Gualano MR, **Osella-Abate S**, Scaioli G, Marra E, Bert F, Faure E, Baduel ES, Balagna E, Quaglino P, Fierro MT, Siliquini R, Ribero S. *Br J Dermatol.* 2017 Apr 7. doi: 10.1111/bjd.15552. [Epub ahead of print]
63. Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. Zugna D, Senetta R, Osella-Abate S, Fierro MT, Pisacane A, Zaccagna A, Sapino A, Bataille V, Maurichi A, Picciotto F, Cassoni P, Quaglino P, Ribero S. *Br J Cancer.* 2017 Nov 9. doi: 10.1038/bjc.2017.397.
64. Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. Zugna D, Senetta R, **Osella-Abate S**, Fierro MT, Pisacane A, Zaccagna A, Sapino A, Bataille V, Maurichi A, Picciotto F, Cassoni P, Quaglino P, Ribero S. *Br J Cancer.* 2018 Feb 6;118(3):398-404. doi: 10.1038/bjc.2017.397. Epub 2017 Nov 9.
65. The role of the AR/ER ratio in ER-positive breast cancer patients. Rangel N, Rondon-Lagos M, Annaratone L, **Osella-Abate S**, Metovic J, Mano MP, Bertero L, Cassoni P, Sapino A, Castellano I. *Endocr Relat Cancer.* 2018 Mar;25(3):163-172.
66. CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Coccorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, **Osella-Abate S**, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI). *Eur J Cancer.* 2018 Jul;97:59-61.
67. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients. Rangel N, Fortunati N, **Osella-Abate S**, Annaratone L, Isella C, Catalano MG, Rinella L, Metovic J, Boldorini R, Balmativola D, Ferrando P, Marano F, Cassoni P, Sapino A, Castellano I. *BMC Cancer.* 2018 Jul 3;18(1):703. doi: 10.1186/s12885-018-4624-y.
68. Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. Bertero L, Anfossi V, **Osella-Abate S**, Disanto MG, Mantovani C, Zenga F, Rudà R,

	<p>Garbossa D, Soffiotti R, Ricardi U, Papotti M, Cassoni P. PLoS One. 2018 Sep 5;13(9):</p> <p>69. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. Ribero S, Malavenda O, Fava P, Astrua C, Marra E, Osella-Abate S, Sanlorenzo M, Caliendo V, Fierro MT, Quaglino P. <i>Future Oncol</i>. 2019 Jan;15(2):133-139.</p> <p>70. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI). <i>Cancer Immunol Immunother</i>. 2019 Jan;68(1):97-107.</p> <p>71. Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. Ribero S, Galli F, Osella-Abate S, Bertero L, Cattaneo L, Merelli B, Tondini C, Ghilardi L, De Giorgi V, Ocelli M, Quaglino P, Cassoni P, Palmieri G, Massi D, Mandala M; Italian Melanoma Intergroup. <i>J Am Acad Dermatol</i>. 2019 Jan;80(1):99-105.</p> <p>72. ALK expression favorably impacts the prognosis of <i>NRAS</i>-mutated metastatic melanomas. Osella-Abate S, Mereu E, Pellegrino E, Bergaggio E, Ribero S, Bertero L, Lisa F, Fierro MT, Giulio Papotti M, Piva R. <i>Oncol Lett</i>. 2018 Dec;16(6):7091-7096. doi: 10.3892/ol.2018.9560.</p> <p>73. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. Bertero L, Dalla Dea G, Osella-Abate S, Botta C, Castellano I, Morra I, Pollo B, Calatozzolo C, Patriarca S, Mantovani C, Rudà R, Tardivo V, Zenga F, Garbossa D, Papotti M, Soffiotti R, Ricardi U, Cassoni P. <i>J Neuropathol Exp Neurol</i>. 2019 [Epub ahead of print]</p> <p>74. <i>TERT</i> Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. Osella-Abate S, Bertero L, Senetta R, Mariani S, Lisa F, Coppola V, Metovic J, Pasini B, Puig S S, Fierro MT, Manrique-Silva E, Kumar R, Nagore E, Cassoni P, Ribero S. <i>Cancers (Basel)</i>. 2019 Mar 30;11(4). pii: E452. doi: 10.3390/cancers11040452.</p>
--	---

<p>Grants</p>	<ul style="list-style-type: none"> - Fondazione CRT 2016: Project “TERT e melanoma metastatico: un potenziale fattore prognostico per una terapia personalizzata” (30000 euro) - Ricerca locale ex60% 2015 University of Turin; Project “ ALK^{AT1}: Valutazione della trascrizione alternativa di ALK nel melanoma cutaneo (4157 euro) - Ricerca locale ex60% 2017 University of Turin: Project “IRF4 and TERT genetic variant: a synergic effect on metastatic melanoma patients survival?” (8406 euro) - Ricerca locale ex60% 2018 University of Turin: Project “Phenotypical characterization of immune cells associated with histological regression in cutaneous melanoma: what is its role in daily practice” (4030 euro)
---------------	--